Radiation, immunotherapy and targeted therapy for early-stage lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have stage II to IIIA non-small cell lung cancer (NSCLC) that has been confirmed by a biopsy.
- Your tumors must be able to be removed with surgery and treated with a special type of radiation therapy (hypofractionated radiotherapy).
- Your cancer must not have certain gene mutations (EGFR, ALK, or ROS1).
- You should be in good general health (ECOG performance status 0 or 1) and expected to live at least 1 year.
- You must not have had any prior cancer treatment (chemotherapy, radiation, targeted therapy, or immunotherapy) for this cancer.
- Women who could become pregnant must use effective birth control and have a negative pregnancy test; men must also use birth control during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.